Seeking Alpha

More on Pfizer (PFE) Q2: net profit +25% to $3.25B despite a 9% fall in revenue following...

More on Pfizer (PFE) Q2: net profit +25% to $3.25B despite a 9% fall in revenue following Lipitor's patent expiration, with the bottom line benefiting from major cost cuts. Pfizer plans to file to sell 20% of its animal health business, to be called Zoetis, in an IPO in mid-August. Shares +0.8% premarket.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs